RGNX — REGENXBIO Inc. Stock Price, Chart & AI Report

Negative Apr 15, 2026 • 00:05 UTC Benzinga • Djs Law Group

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

REGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor. Shareholders who purchased shares between February 9, 2022 and January 27, 2026 are encouraged to contact DJS Law Group regarding potential recovery.

RGNX securities fraud class action lawsuit RGX-111 FDA clinical hold misleading statements investor losses biotech litigation

Sentiment note

The company is facing a class action lawsuit for securities violations, specifically for making false and misleading statements about product safety and efficacy while concealing adverse information. An FDA clinical hold on a key product candidate due to a tumor development in a trial participant represents a significant setback and regulatory concern.

Negative Apr 14, 2026 • 19:51 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

Pomerantz Law Firm has filed class action lawsuits against REGENXBIO Inc., AMC Entertainment Holdings, Inc., and Upstart Holdings, Inc. for alleged securities fraud and unlawful business practices. The REGENXBIO lawsuit was triggered by an FDA clinical hold on its gene therapy candidates RGX-111 and RGX-121, which caused the stock to fall 17.9% on January 28, 2026. Investors with losses are urged to contact the firm by the April 14, 2026 deadline to potentially serve as lead plaintiff.

RGNX AMC UPST class action lawsuit securities fraud FDA clinical hold gene therapy stock price decline

Sentiment note

Company faces class action lawsuit for alleged securities fraud following FDA clinical hold on two investigational gene therapies (RGX-111 and RGX-121), resulting in a 17.9% stock price decline on the announcement date.

Negative Apr 14, 2026 • 19:46 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, REGENXBIO Inc., and Upstart Holdings, alleging securities fraud and unlawful business practices. The AMC lawsuit specifically concerns APE preferred equity unit holders who were excluded from a special dividend following conversion to common stock due to an undisclosed loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.

RGNX UPST AMC class action lawsuit securities fraud APE preferred equity units special dividend Certificate of Designations

Sentiment note

Subject of a class action lawsuit filed by Pomerantz LLP, indicating allegations of securities violations or corporate misconduct affecting investors.

Negative Apr 14, 2026 • 13:00 UTC GlobeNewswire Inc. • Portnoy Law Firm

Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors

REGENXBIO investors can file a class action lawsuit for securities purchased between February 9, 2022 and January 27, 2026. The lawsuit alleges the company made false statements about the safety and efficacy of its RGX-111 gene therapy. On January 28, 2026, REGENXBIO announced the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock to fall nearly 18%.

RGNX class action lawsuit REGENXBIO RGX-111 gene therapy FDA clinical hold securities fraud investor losses

Sentiment note

The company faces a class action lawsuit alleging false and misleading statements about drug safety and efficacy. An FDA clinical hold on its lead candidate RGX-111 due to a serious adverse event (CNS tumor) in a trial participant resulted in an 18% stock price decline, indicating significant regulatory and commercial setbacks.

Negative Apr 12, 2026 • 15:14 UTC GlobeNewswire Inc. • Rosen Law Firm

REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX

Rosen Law Firm is reminding REGENXBIO investors who purchased securities between February 9, 2022 and January 27, 2026 of the April 14, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements about the efficacy and safety of its RGX-111 gene therapy trial while providing overwhelmingly positive public assertions, resulting in investor damages.

RGNX securities class action RGX-111 gene therapy Hurler syndrome material misstatement investor damages lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding clinical trial safety and efficacy data for its lead product candidate RGX-111, resulting in investor losses.

Negative Apr 6, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against REGENXBIO Inc. alleging that the company made materially false and misleading statements regarding its RGX-111 gene therapy development and clinical trial results. The lawsuit covers investors who purchased securities between February 9, 2022 and January 27, 2026, with a lead plaintiff deadline of April 14, 2026.

RGNX class action lawsuit securities fraud RGX-111 gene therapy Mucopolysaccharidosis Type I clinical trial investor harm

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements about its RGX-111 therapy development, clinical trial results, and efficacy/safety profile. This represents significant legal and reputational risk to the company.

Negative Apr 6, 2026 • 08:04 UTC Benzinga • The Schall Law Firm

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking lead plaintiffs for a securities fraud class action lawsuit against REGENXBIO Inc. The lawsuit alleges the company made false and misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data while presenting overwhelmingly positive statements to investors. The fraud was allegedly revealed when an intraventricular CNS tumor was discovered in a study participant. Investors who purchased securities between February 9, 2022 and January 27, 2026 are encouraged to join the case.

RGNX securities fraud class action lawsuit RGX-111 false statements product safety CNS tumor investor damages

Sentiment note

The company is accused of making false and misleading statements to investors about product candidate RGX-111, concealing negative efficacy and safety data. The discovery of an intraventricular CNS tumor in a study participant exposed the fraud, resulting in investor losses and a securities class action lawsuit.

Negative Apr 5, 2026 • 23:52 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

A securities class action lawsuit has been filed against REGENXBIO, Inc. for allegedly providing materially false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial while making positive assertions to investors. The firm is seeking a lead plaintiff by April 14, 2026, for investors who purchased securities between February 9, 2022 and January 27, 2026.

RGNX securities class action REGENXBIO RGX-111 gene therapy Hurler syndrome material misstatement investor losses

Sentiment note

The company is the subject of a securities class action lawsuit alleging it provided false and misleading statements about the efficacy and safety of its RGX-111 trial while making overwhelmingly positive assertions to investors, resulting in investor damages when the true details emerged.

Negative Apr 5, 2026 • 23:29 UTC GlobeNewswire Inc. • Rosen Law Firm

TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPC

Rosen Law Firm is notifying investors in BlackRock TCP Capital Corp. (TCPC) and other companies about ongoing securities class action lawsuits. The firm is seeking a lead plaintiff by the April 6, 2026 deadline. According to the lawsuit, BlackRock TCP made materially false statements regarding investment valuations, portfolio quality, and net asset value, resulting in investor losses.

TCPC RGNX RARE securities class action lead plaintiff deadline material misstatement investment valuation net asset value

Sentiment note

The company is mentioned as subject to a securities class action lawsuit by Rosen Law Firm, indicating alleged securities violations.

Negative Apr 5, 2026 • 01:12 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

A securities class action lawsuit has been filed against REGENXBIO, Inc. for allegedly providing investors with false and misleading statements regarding its RGX-111 gene therapy candidate. The firm claims defendants made overwhelmingly positive assertions about the drug's trial success while concealing material adverse facts about efficacy and safety. Investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026 may be eligible for compensation. The lead plaintiff deadline is April 14, 2026.

RGNX securities class action RGX-111 gene therapy Hurler syndrome false statements investor compensation lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding clinical trial data for its lead product candidate RGX-111. Investors claim they suffered damages when true details about efficacy and safety concerns entered the market.

Negative Apr 3, 2026 • 18:03 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire announces class action lawsuits against PayPal Holdings and REGENXBIO Inc. PayPal faces allegations of providing false revenue projections and unachievable 2027 targets, leading to a 20% stock decline after disappointing Q4 2025 results. REGENXBIO is sued over concealed safety concerns regarding its RGX-111 gene therapy, which experienced a 17.8% stock drop following an FDA clinical hold due to a tumor found in a trial participant.

PYPL RGNX class action lawsuit securities fraud misleading statements PayPal REGENXBIO stock decline

Sentiment note

Company faces class action lawsuit for concealing material adverse facts about RGX-111 gene therapy safety and efficacy. FDA placed clinical hold on the drug after a tumor was found in a trial participant, causing stock to drop 17.8% in one day.

Negative Apr 1, 2026 • 21:56 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNOW

Rosen Law Firm is soliciting investors who purchased securities of Snowflake Inc., REGENXBIO Inc., and Plug Power Inc. during specified class periods to join ongoing securities class action lawsuits. The lawsuits allege that these companies made misleading positive statements about their businesses while failing to disclose material negative information that subsequently impacted stock prices.

SNOW RGNX PLUG securities class action investor lawsuit misleading statements lead plaintiff deadline contingency fee

Sentiment note

Company is subject to securities class action lawsuit; specific allegations not detailed in provided excerpt but implied similar misconduct involving misleading investor statements.